Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node negative breast cancer patients

Sieuwerts, Anieta M.; Look,; Gelder, Marion E. Meijer–van; Timmermans, Mieke; Portengen, H.; Klijn, J.G.M.; Foekens, J.A.

doi:10.1016/s1359-6349(06)80304-6

Cited by 24 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mir-21 functions as an oncogene because it is overexpressed in tumor compared with the normal tissues (Vandesompele et al, 2002;Sieuwerts et al, 2006;Kulshreshtha et al, 2007;Smid et al, 2008) and its suppression inhibits cell growth through activation of apoptosis pathways causing activation of effector caspases and increased cell death (Kulshreshtha et al, 2007;Smid et al, 2008). Endogenous angiogenesis inhibitors TIMPs are necessary to block the mitogenic stimuli in the vascular endothelium (Curran et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Metastasis-related Gene Expression in Egyptian Breast Cancer Patients

Hafez

Hassan²,

Zekri³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Metastasis-related Gene Expression in Egyptian Breast Cancer Patients

Hafez

Hassan²,

Zekri³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Cyclin E2 expression has been associated with poor outcome in ER-positive breast cancer (109), and cyclin E2 is included in genes that predict disease progression in either tamoxifen-resistant breast cancer or metastatic breast cancer, whereas cyclin E1 is absent (110,111). Cyclin E1 overexpression can reduce antiestrogen sensitivity in vitro (112,113), but cyclin E2 has not been studied in this context, although it is strongly estrogen regulated (114).…”

Section: Cell Cycle Regulators Associated With Resistance To Tamoxifenmentioning

confidence: 99%

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

et al. 2014

View full text Add to dashboard Cite

Abstract. Anti-estrogens such as tamoxifen are widely used in the clinic to treat estrogen receptor-positive breast tumors. Patients with estrogen receptor-positive breast cancer initially respond to treatment with anti-hormonal agents such as tamoxifen, but remissions are often followed by the acquisition of resistance and, ultimately, disease relapse. The development of a rationale for the effective treatment of tamoxifen-resistant breast cancer requires an understanding of the complex signal transduction mechanisms. In the present study, we explored some mechanisms associated with resistance to tamoxifen, such as pharmacologic mechanisms, loss or modification in estrogen receptor expression, alterations in co-regulatory proteins and the regulation of the different signaling pathways that participate in different cellular processes such as survival, proliferation, stress, cell cycle, inhibition of apoptosis regulated by the Bcl-2 family, autophagy, altered expression of microRNA, and signaling pathways that regulate the epithelial-mesenchymal transition in the tumor microenvironment. Delineation of the molecular mechanisms underlying the development of resistance may aid in the development of treatment strategies to enhance response and compromise resistance.

show abstract

“…This report is as much as possible in line with the REMARK guidelines (McShane et al, 2006). Primary breast tumours were obtained from patients with detailed clinical follow-up as previously described (Sieuwerts et al, 2006Jansen et al, 2007;Meijer et al, 2008Meijer et al, , 2009Van Agthoven et al, 2009a). All patients underwent breast surgery for breast cancer from 1978 through 2000.…”

Section: Patient Samplesmentioning

confidence: 99%

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: Endocrine therapies of breast cancer are effective but ultimately fail because of the development of treatment resistance. We have previously revealed several genes leading to tamoxifen resistance in vitro by retroviral insertion mutagenesis. To understand the manner in which these genes yield tamoxifen resistance, their effects on global gene expression were studied and those genes resulting in a distinct gene expression profile were further investigated for their clinical relevance. METHODS: Gene expression profiles of 69 human breast cancer cell lines that were made tamoxifen resistant through retroviral insertion mutagenesis were obtained using oligonucleotide arrays and analysed with bioinformatic tools. mRNA levels of NCOR2 and CITED2 in oestrogen receptor-positive breast tumours were determined by quantitative RT -PCR. mRNA levels were evaluated for association with metastasis-free survival (MFS) in 620 patients with lymph node-negative primary breast cancer who did not receive systemic adjuvant therapy, and with clinical benefit in 296 patients receiving tamoxifen therapy for recurrent breast cancer. RESULTS: mRNA expression profiles of most tamoxifen-resistant cell lines were strikingly similar, except for the subgroups of cell lines in which NCOR2 or CITED2 were targeted by the retrovirus. Both NCOR2 and CITED2 mRNA levels were associated with MFS, that is, tumour aggressiveness, independently of traditional prognostic factors. In addition, high CITED2 mRNA levels were predictive for a clinical benefit from first-line tamoxifen treatment in patients with advanced disease. CONCLUSIONS: Most retrovirally targeted genes yielding tamoxifen resistance in our cell lines do not impose a distinctive expression profile, suggesting that their causative role in cell growth may be accomplished by post-transcriptional processes. The associations of NCOR2 and CITED2 with outcome in oestrogen receptor-positive breast cancer patients underscore the clinical relevance of functional genetic screens to better understand disease progression, which may ultimately lead to the development of improved treatment options.

show abstract

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node negative breast cancer patients

Cited by 24 publications

References 0 publications

MicroRNAs and Metastasis-related Gene Expression in Egyptian Breast Cancer Patients

MicroRNAs and Metastasis-related Gene Expression in Egyptian Breast Cancer Patients

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer

Contact Info

Product

Resources

About